RIGEL PHARMACEUTICALS INC (RIGL): Nasdaq/NYSE listing notice — Rigel Pharma gets Nasdaq deficiency notice for bid price below $1.00

RIGEL PHARMACEUTICALS INC

Received Nasdaq deficiency letter on Nov 27, 2023 for bid price below $1.00 for 30 consecutive business days.
Has 180 calendar days, until May 28, 2024, to regain compliance by closing at $1.00+ for 10 consecutive days.
If not compliant by May 28, may be eligible for additional 180-day period if transfers to Nasdaq Capital Market.
Company may consider a reverse stock split to cure deficiency; no immediate effect on listing.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.97

RIGEL PHARMACEUTICALS INC received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1), 5810(c)(3)(A)

Exact text from the filing

November 27, 2023, Rigel Pharmaceuticals, Inc. (“Rigel”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) notifying Rigel that, for the last 30 consecutive business days, the bid price for Rigel’s common stock, par value $0.001 per share (the “Common Stock”), closed below the $1.00 per share minimum bid price requirement for continued inclusion on the Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Bid Price Requirement”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A) (the “Compli

View on SEC.gov

20 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

RIGEL PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001104659-23-122171

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.